Overview
Sponsor-declared trial summary
Chronic Kidney Disease
To demonstrate whether orforglipron is superior to placebo in reducing the risk for major CV events.
Key facts
- Sponsor
- Eli Lilly & Co.
- Participant type
- Patients
- Age range
- 18-64 years, 65+ years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Cardiovascular Diseases [C14]
- Trial duration
- 7 May 2026 → ongoing
- Decision date (initial)
- 2026-03-01
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- No
External identifiers
- EU CT number
- 2025-523123-22-00
- WHO UTN
- U1111-1326-0582
Trial design
CTIS Part I — objectives, methods, condition coding
Main objective
Scope: Safety, Efficacy
To demonstrate whether orforglipron is superior to placebo in reducing the risk for major CV events.
Conditions and MedDRA coding
Chronic Kidney Disease
Eligibility criteria
Principal inclusion / exclusion criteria as submitted by sponsor
Inclusion criteria 1
- Have heart disease, kidney disease, or both
Exclusion criteria 3
- Have type 1 diabetes
- Have had a serious heart condition within 60 days of screening
- Have New York Heart Association Functional Classification Class IV heart failure
Endpoints
Primary and secondary outcome measures (English text)
Primary endpoints 1
- Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events Composite endpoint includes nonfatal myocardial infarction, nonfatal stroke, hospitalization or urgent visit due to heart failure, coronary revascularization, or all-cause death [Time Frame: Baseline up to end of study (about 5 years)]
Investigational products
Investigational medicinal products (IMPs), comparators, placebo, auxiliary
Test 6
PRD12263027 · Product
- Active substance
- Orforglipron Hemicalcium
- Substance synonyms
- Orforglipron calcium, Calcium bis{3-[(1S,2S)-1-({2-(4-fluoro-3,5-dimethylphenyl)-3-({3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}carbonyl)-5-[(4S)-2,2-dimethyloxan-4-yl]-1H-indol-1-yl}-2-methylcyclopropyl]-5-oxo-1,2,4-oxadiazol-4(5H)-ide}, LY3502970 hemicalcium
- Pharmaceutical form
- TABLET
- Route of administration
- ORAL
- Max daily dose
- 0 mg milligram(s)
- Max total dose
- 0 mg milligram(s)
- Max treatment duration
- 60 Month(s)
- Authorisation status
- Not Authorised
- MA holder
- ELI LILLY AND COMPANY LIMITED
- Paediatric formulation
- No
- Orphan designation
- No
PRD12263031 · Product
- Active substance
- Orforglipron Hemicalcium
- Substance synonyms
- Orforglipron calcium, Calcium bis{3-[(1S,2S)-1-({2-(4-fluoro-3,5-dimethylphenyl)-3-({3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}carbonyl)-5-[(4S)-2,2-dimethyloxan-4-yl]-1H-indol-1-yl}-2-methylcyclopropyl]-5-oxo-1,2,4-oxadiazol-4(5H)-ide}, LY3502970 hemicalcium
- Pharmaceutical form
- TABLET
- Route of administration
- ORAL
- Max daily dose
- 0 mg milligram(s)
- Max total dose
- 0 mg milligram(s)
- Max treatment duration
- 60 Month(s)
- Authorisation status
- Not Authorised
- MA holder
- ELI LILLY AND COMPANY LIMITED
- Paediatric formulation
- No
- Orphan designation
- No
PRD12263032 · Product
- Active substance
- Orforglipron Hemicalcium
- Substance synonyms
- Orforglipron calcium, Calcium bis{3-[(1S,2S)-1-({2-(4-fluoro-3,5-dimethylphenyl)-3-({3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}carbonyl)-5-[(4S)-2,2-dimethyloxan-4-yl]-1H-indol-1-yl}-2-methylcyclopropyl]-5-oxo-1,2,4-oxadiazol-4(5H)-ide}, LY3502970 hemicalcium
- Pharmaceutical form
- TABLET
- Route of administration
- ORAL
- Max daily dose
- 0 mg milligram(s)
- Max total dose
- 0 mg milligram(s)
- Max treatment duration
- 60 Month(s)
- Authorisation status
- Not Authorised
- MA holder
- ELI LILLY AND COMPANY LIMITED
- Paediatric formulation
- No
- Orphan designation
- No
PRD12263029 · Product
- Active substance
- Orforglipron Hemicalcium
- Substance synonyms
- Orforglipron calcium, Calcium bis{3-[(1S,2S)-1-({2-(4-fluoro-3,5-dimethylphenyl)-3-({3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}carbonyl)-5-[(4S)-2,2-dimethyloxan-4-yl]-1H-indol-1-yl}-2-methylcyclopropyl]-5-oxo-1,2,4-oxadiazol-4(5H)-ide}, LY3502970 hemicalcium
- Pharmaceutical form
- TABLET
- Route of administration
- ORAL
- Max daily dose
- 0 mg milligram(s)
- Max total dose
- 0 mg milligram(s)
- Max treatment duration
- 60 Month(s)
- Authorisation status
- Not Authorised
- MA holder
- ELI LILLY AND COMPANY LIMITED
- Paediatric formulation
- No
- Orphan designation
- No
PRD12263028 · Product
- Active substance
- Orforglipron Hemicalcium
- Substance synonyms
- Orforglipron calcium, Calcium bis{3-[(1S,2S)-1-({2-(4-fluoro-3,5-dimethylphenyl)-3-({3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}carbonyl)-5-[(4S)-2,2-dimethyloxan-4-yl]-1H-indol-1-yl}-2-methylcyclopropyl]-5-oxo-1,2,4-oxadiazol-4(5H)-ide}, LY3502970 hemicalcium
- Pharmaceutical form
- TABLET
- Route of administration
- ORAL
- Max daily dose
- 0 mg milligram(s)
- Max total dose
- 0 mg milligram(s)
- Max treatment duration
- 60 Month(s)
- Authorisation status
- Not Authorised
- MA holder
- ELI LILLY AND COMPANY LIMITED
- Paediatric formulation
- No
- Orphan designation
- No
PRD12263030 · Product
- Active substance
- Orforglipron Hemicalcium
- Substance synonyms
- Orforglipron calcium, Calcium bis{3-[(1S,2S)-1-({2-(4-fluoro-3,5-dimethylphenyl)-3-({3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}carbonyl)-5-[(4S)-2,2-dimethyloxan-4-yl]-1H-indol-1-yl}-2-methylcyclopropyl]-5-oxo-1,2,4-oxadiazol-4(5H)-ide}, LY3502970 hemicalcium
- Pharmaceutical form
- TABLET
- Route of administration
- ORAL
- Max daily dose
- 0 mg milligram(s)
- Max total dose
- 0 mg milligram(s)
- Max treatment duration
- 60 Month(s)
- Authorisation status
- Not Authorised
- MA holder
- ELI LILLY AND COMPANY LIMITED
- Paediatric formulation
- No
- Orphan designation
- No
Placebo 1
N/A · Product
- Other product name
- N/A
- Pharmaceutical form
- N/A
- ATC code
- N/A — N/A
- Marketing authorisation
- N/A
- MA holder
- N/A
- MA country
- Iceland
- Paediatric formulation
- No
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Eli Lilly & Co.
- Sponsor organisation
- Eli Lilly & Co.
- Address
- 1 Lilly Corporate Center
- City
- Indianapolis
- Postcode
- 46285-0001
- Country
- United States
Scientific contact point
- Organisation
- Eli Lilly & Co.
- Contact name
- Lilly Clinical Trials information desk
Public contact point
- Organisation
- Eli Lilly & Co.
- Contact name
- Lilly Clinical Trials information desk
Third parties 9
| Organisation | City, country | Duties |
|---|---|---|
| Pharmaceutical Product Development LLC ORG-100016999
|
Highland Heights, United States | Laboratory analysis |
| Trialbee AB ORG-100051369
|
Malmo, Sweden | Other |
| Pharmaserve Lilly S.A.C.I. ORG-100005347
|
Kifisia, Greece | On site monitoring, Code 12, Other, Code 2, Code 5 |
| Clariness GmbH ORG-100045306
|
Hamburg, Germany | Other |
| Pharmaceutical Product Development, LLC ORL-000015921
|
Shanghai, China | Laboratory analysis |
| PPD Global Central Labs ORG-100046496
|
Zaventem, Belgium | Laboratory analysis |
| PPD Global Central Labs (S) Pte Ltd ORG-100041754
|
Singapore, Singapore | Laboratory analysis |
| Iqvia Biotech LLC ORG-100008704
|
Durham, United States | On site monitoring |
| Veeva Systems Inc. ORG-100006053
|
Pleasanton, United States | Data management |
Locations
17 EU/EEA countries · 209 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Austria | Ongoing, recruiting | 43 | 8 |
| Belgium | Ongoing, recruiting | 118 | 14 |
| Bulgaria | Authorised, recruitment pending | 96 | 10 |
| Czechia | Ongoing, recruiting | 194 | 14 |
| Estonia | Authorised, recruitment pending | 78 | 4 |
| France | Ongoing, recruiting | 61 | 14 |
| Germany | Ongoing, recruiting | 67 | 8 |
| Greece | Ongoing, recruiting | 67 | 8 |
| Hungary | Ongoing, recruiting | 121 | 15 |
| Italy | Ongoing, recruiting | 90 | 15 |
| Lithuania | Authorised, recruiting | 85 | 7 |
| Netherlands | Authorised, recruitment pending | 148 | 23 |
| Poland | Ongoing, recruiting | 211 | 21 |
| Romania | Authorised, recruitment pending | 182 | 20 |
| Slovakia | Ongoing, recruiting | 84 | 11 |
| Spain | Ongoing, recruiting | 148 | 16 |
| United States | 0 | 1 | |
| Rest of world
Serbia, Colombia, South Africa, Japan, China, Thailand, Israel, Taiwan, Mexico, Brazil, Korea, Republic of, India, Australia, Tunisia, United Kingdom, Malaysia, Turkey, New Zealand, Canada, Argentina, Ukraine, Philippines
|
— | 5,347 | — |
Investigational sites
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Austria | 2026-05-11 | 2026-05-13 | |||
| Belgium | 2026-05-13 | 2026-05-21 | |||
| Czechia | 2026-05-15 | 2026-05-19 | |||
| France | 2026-05-14 | 2026-05-19 | |||
| Germany | 2026-05-11 | 2026-05-19 | |||
| Greece | 2026-05-07 | 2026-05-08 | |||
| Hungary | 2026-05-18 | 2026-05-20 | |||
| Italy | 2026-05-12 | 2026-05-19 | |||
| Lithuania | 2026-06-02 | ||||
| Poland | 2026-05-11 | 2026-05-13 | |||
| Slovakia | 2026-05-11 | 2026-05-13 | |||
| Spain | 2026-05-13 | 2026-05-14 |
Results and documents
Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial
Documents 288 files
Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.
| Type | Title | Version |
|---|---|---|
| Protocol (for publication) | D1_Protocol 2025-523123-22-00_Redacted | a |
| Protocol (for publication) | D1_Protocol addendum EU_2025-523123-22-00_Redacted | 3 |
| Protocol (for publication) | D1_Protocol Addendum_2025-523123-22-00_GR_Redacted | 3 |
| Protocol (for publication) | D1_Protocol_2025-523123-22-00_GR_Redacted | a |
| Protocol (for publication) | D4_Study Participant Contact Card_GR | 2 |
| Recruitment arrangements (for publication) | 1_Recruitment and Informed consent procedure_GR | 1 |
| Recruitment arrangements (for publication) | K1_Informed consent and Patient Recruitment Procedure | 2.0 |
| Recruitment arrangements (for publication) | K1_Informed consent and patient recruitment procedure_AT | 2 |
| Recruitment arrangements (for publication) | K1_Informed consent and patient recruitment procedure_SK | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment and consenting procedure | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment and informed consent procedure | 2 |
| Recruitment arrangements (for publication) | K1_Recruitment and informed consent procedure_TC | 2 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements | 2.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements | 1.1 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_lt | v2 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements_PL | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangments_BG | 2 |
| Recruitment arrangements (for publication) | K1_Recruitment material_Brochure | 2.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Material_Brochure Master | 2 |
| Recruitment arrangements (for publication) | K1_Recruitment material_Flyer | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Material_Flyer Master | 2 |
| Recruitment arrangements (for publication) | K1_Recruitment Material_Letter Doctor Referral_Master_redacted | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment Material_Letter Doctor to Patient_Master | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment material_Letter-Doctor-Referral_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment material_Letter-Doctor-to-Patient | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment material_Poster | 2.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Material_Poster Master | 2 |
| Recruitment arrangements (for publication) | K1_Recruitment Material_PPT_Doctor Referral_Master_redacted | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment material_PPT-Dr-Referral_Redacted | 2.0 |
| Recruitment arrangements (for publication) | K1_Recruitment material_Trialbee_Digital Marketing Content | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Material_Trialbee_Digital marketing content | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment material_Trialbee_Global Privacy Policy | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Material_Trialbee_Global Privacy policy | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment material_Trialbee_Landing Page | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Material_Trialbee_Landing page | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment Material_Trialbee_Overview SuppInfo | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment material_Trialbee_OverviewSupplementaryInformation | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment material_Trialbee_Secondary Assessment_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Material_TrialBee_Secondary Assessment_redacted | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment Material_Trialbee_Self assessment_redacted | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment material_Trialbee_Self_Assessment_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_ Recruitment material_Brochure BEDU | 1 |
| Recruitment arrangements (for publication) | K2_ Recruitment material_Brochure BEFR | 2.0 |
| Recruitment arrangements (for publication) | K2_ Recruitment material_Flyer BEDU | 2.0 |
| Recruitment arrangements (for publication) | K2_ Recruitment material_Flyer BEFR | 2.0 |
| Recruitment arrangements (for publication) | K2_ Recruitment material_Poster BEFR | 2.0 |
| Recruitment arrangements (for publication) | K2_Brochure_Master_RO | 1 |
| Recruitment arrangements (for publication) | K2_CT_Outcomes-study-leaflet | 1 |
| Recruitment arrangements (for publication) | K2_Flyer_Master_RO | 2.0 |
| Recruitment arrangements (for publication) | K2_Letter-Doctor-to-Patient_Master_RO | 2.0 |
| Recruitment arrangements (for publication) | K2_List of paticipating sites_SK_clean_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_Poster_Master_RO | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment and Informed Consent Procedure | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_ Brochure | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment material_ Flyer | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment material_ LetterDoctorReferral_redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Brochure | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Brochure | 3.1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Brochure_GR | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Brochure_Master | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Brochure_Master | 3 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Brochure_Master_ES | 2.1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Brochure_Master_ITA | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Brochure_Master_SK | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Digitalmarketing Content | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Doctor Letter to Patient | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Flyer | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Flyer | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Flyer | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Flyer_GR | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Flyer_Master | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Flyer_Master_ES | 2.1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Flyer_Master_ITA | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Flyer_Master_SK | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_LandingPage | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter Doctor Referral_Master_BG_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter Doctor Referral_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter Doctor to Patient | 2.1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter doctor to patient BEDU | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter doctor to patient BEFR | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter Doctor to Patient_GR | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter Doctor to patient_ITA | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter Doctor to Patient_Master | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter-Doctor-Referral_Master_SK_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter-Doctor-to-Patient | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter-Doctor-to-Patient_Master_ES | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter-Doctor-to-Patient_Master_SK | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_LetterDoctortoPatient | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Overview | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Poster | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Poster | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Poster | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Poster | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Poster BEDU | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Poster_GR | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Poster_Master | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Poster_Master_ES | 2.1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Poster_Master_ITA | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Poster_Master_SK | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Secondary Assessment_redacted | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_SelfAssessment_redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Trialbee Digital Marketing Content_BEDU | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Trialbee Digital Marketing Content_BEFR | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Trialbee Global Privacy Policy_BEDU | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Trialbee Global Privacy Policy_BEFR | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Trialbee Landing Page_BEDU | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Trialbee Landing Page_BEFR | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Trialbee Overview Supplementary Information_BEDU | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Trialbee Overview Supplementary Information_BEFR | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Trialbee Secondary Assessment_BEDU_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Trialbee Secondary Assessment_BEFR_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Trialbee Self Assessment_BEDU_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Trialbee Self Assessment_BEFR_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Trialbee_Digital Marketing Content | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Trialbee_Digital Marketing Content | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Trialbee_Digital Marketing Content | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Trialbee_Digital Marketing Content_PL | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Trialbee_Global Privacy Policy | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Trialbee_Global Privacy Policy | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Trialbee_Global Privacy Policy | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Trialbee_Global Privacy Policy_PL | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Trialbee_Landing Page | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Trialbee_Landing Page | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Trialbee_Overview Supplementary Information | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Trialbee_Overview Supplementary Information | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Trialbee_Overview Supplementary Information | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Trialbee_OverviewSupplementaryInformation_PL | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Trialbee_Patient Community Outreach | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Trialbee_Patient Community Outreach | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Trialbee_Patient Community Outreach | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Trialbee_Patient Community Outreach_PL | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Trialbee_Secondary Assessment_PL_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Trialbee_Secondary Assessment_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Trialbee_Secondary Assessment_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Trialbee_Secondary Assessment_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Trialbee_Self Assessment_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Trialbee_Self_Assessment_PL_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Trialbee_Self_Assessment_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Trialbee_Self_Assessment_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Wervingstekst en beelden voor de rekruteringscampagne Lilly Obesitas Attain | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_ZoomHealth_Privacy Statement | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_ZoomHealth_Screenshots | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_ZoomHealth_TermsofService | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment materials _Letter-Doctor-Referral_Master_v1_LT_21Aug2025_redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment materials__Flyer_Master_v2_LT_21Aug2025 | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment materials_Brochure_Master_EST | 2.1 |
| Recruitment arrangements (for publication) | K2_Recruitment materials_Brochure_Master_v2_LT_21Aug2025 | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment materials_Flyer_Master_EST | 2.1 |
| Recruitment arrangements (for publication) | K2_Recruitment materials_Letter-Doctor-Referral_Master_ET_Redacted | 1.2 |
| Recruitment arrangements (for publication) | K2_Recruitment materials_Letter-Doctor-to-Patient_Master_EST | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment materials_Letter-Doctor-to-Patient_Master_v1_LT_06Aug2025 | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment materials_Poster_Master_EST | 2.1 |
| Recruitment arrangements (for publication) | K2_Recruitment materials_Poster_Master_v2_LT_21Aug2025 | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment Materials_Trialbee_Digital Marketing Content | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Materials_Trialbee_Global Privacy Policy | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Materials_Trialbee_Landing Page | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Materials_Trialbee_Overview Supplementary Information | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Materials_Trialbee_Secondary Assessment_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Materials_Trialbee_Self_Assessment_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Trialbee_Digital Marketing Content_ro-RO | 1 |
| Recruitment arrangements (for publication) | K2_Trialbee_Global Privacy Policy_ro-RO | 1 |
| Recruitment arrangements (for publication) | K2_Trialbee_Landing Page_ro-RO | 1 |
| Recruitment arrangements (for publication) | K2_Trialbee_OverviewSupplementaryInformation_ro-RO | 1 |
| Recruitment arrangements (for publication) | K2_Trialbee_Secondary Assessment_ro-RO_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Trialbee_Self_Assessment_ro-RO_Redacted | 1 |
| Recruitment arrangements (for publication) | K3_Additional document_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K3_List of planned sites_Redacted | 2 |
| Subject information and informed consent form (for publication) | L1_ICF Sponsor Statement_Redacted | 1 |
| Subject information and informed consent form (for publication) | L1_ICF_Main_GR_Redacted | 1 |
| Subject information and informed consent form (for publication) | L1_Main ICF_Redacted | 1 |
| Subject information and informed consent form (for publication) | L1_Main TLC_DE_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Addendum genetic samples_Redacted | 1.2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_lt_Redacted | V1.0LTU2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF main_Redacted | 1.2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_RU_ee_Redacted | 1.0EST2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_ Addendum_Pregnant Participant_redacted | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_ Addendum_Pregnant Partner | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Addendum ICF_Redacted | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_GZPW_DPA ICF_Redacted | 2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_GZPW_Main ICF_Redacted | 2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_GZPW_Pregnant partner | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_ICF DPA_SK_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_BEDU_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_BEFR_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_ENG_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_Redacted | 1.2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_Redacted | 4.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_SK_clean_Redacted | 1.2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_BG_bg_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_BG_en_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_EST_ee_Redacted | 01EST2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_EST_ru_redacted | 1.0EST2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_redacted | 1.2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_Redacted | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_PL_Main ICF_GZPW_Redacted | 4.2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnant Partner | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnant Partner ICF_SK | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnant Partner_EST_ee | 1.0EST2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnant Partner_RU_ee | 1.0EST2.0 |
| Subject information and informed consent form (for publication) | L2_ Other subject information material_ZoomHealth documentation | 1 |
| Subject information and informed consent form (for publication) | L2_ Other subject information_Participant Contact Card_BG | NA |
| Subject information and informed consent form (for publication) | L2__Other subject information material_Compensation Information Sheet _v2_LT_06Oct2025_redacted | 2 |
| Subject information and informed consent form (for publication) | L2_Compensation Information Sheet_EST | 2 |
| Subject information and informed consent form (for publication) | L2_List of ssICF contact details_redacted | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject info material_Patient Info Card_SK | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Brochure Master_PL | 2.0 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Card TY End Of Participation_Master_GR | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_compensation sheet_BG_Redacted | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Confidentiality Notice_BG | 2 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Confidentiality Notice_Netherlands_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_CT Card TY Enrollment_Master_GR | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_CT Card TY Screening_Master_GR | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_CT GI AE Brochure_Master_GR | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_CT Outcomes study leaflet_GR | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_CT Supportive Partner Guide_Master_GR | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_CT_GI-AE-Brochure | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_CT_Outcomes-study-leaflet | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_CT_Outcomes-study-leaflet_Master_SK | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_CT_Study-Connect-Participant_Edition2_Master_SK | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_CT_Study-Connect-Participant_Edition4_Master_SK | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_CT_Supportive-Partner-Guide | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_CWM Shopping List_Master_GR | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_CWM_SHOPPING-LIST | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_CWM_SHOPPING-LIST_MASTER_SK | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_End of Study Letter noLD_Master_GR | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_English_Zoom_Privacy Statement | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_English_ZoomHealth_Screenshots | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_English_ZoomHealth_TermsOfService | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Flyer Master_PL | 2.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Letter-Doctor to Patient_PL | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Patient card | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Patient card | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Patient Information Card | 2.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Poster Master_PL | 2.0 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Study Connect Participant_Master_GR_Redacted | 2 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Study Guide_Master_GR_Redacted | 2 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Study Medicine Reminder Magnet_Master_GR | 2 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Study-Connect-Participant_Master_SK_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Study-Connect-Participant_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Study-Guide_Master_SK_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Study-Guide_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Study-Medicine-Reminder-Magnet_Master_SK | 2.0 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Visit Card_Master_GR | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Visit-Card | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Visit-Card_Master_SK | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_ZoomHealth_PrivacyStatement | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_ZoomHealth_PrivacyStatement_PL | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_ZoomHealth_RegulatorySubmission_CoverLetter_GZPW | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_ZoomHealth_Screenshots | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_ZoomHealth_Screenshots_PL | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_ZoomHealth_TermsofService_PL | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information_Compensation Information Sheet_BEDU_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information_Compensation Information Sheet_BEFR_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information_Compensation Information Sheet_ENG_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information_Confidentiality Company Information Notice_ EE | 2 |
| Subject information and informed consent form (for publication) | L2_Other subject information_Confidentiality Company Information Notice_LT | 2 |
| Subject information and informed consent form (for publication) | L2_Other subject information_Participant Contact Card | N/A |
| Subject information and informed consent form (for publication) | L2_Other subject information_Participant Contact Card _LT_05Oct2025 | N/A |
| Subject information and informed consent form (for publication) | L2_Study Participant Contact Card | 1 |
| Subject information and informed consent form (for publication) | L2_Study Participant Contact Card_GR | 2 |
| Subject information and informed consent form (for publication) | L3_Info Re insurance Conditions for Patient_PL | 1.0 |
| Subject information and informed consent form (for publication) | L3_Patient card | 1 |
| Subject information and informed consent form (for publication) | L4_Informed consent and patient recruitment procedure_PL | 2.0 |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis _PL_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis AT_2025-523123-22-00_redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis France 2025-523123-22-00_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis NL 2025-523123-22-00_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_2025-523123-22-00_BG_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_2025-523123-22-00_GR_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_2025-523123-22-00_HU_redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_2025-523123-22-00_LT_26Sep2025 _redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_2025-523123-22-00_SK_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_BEDE_2025-523123-22-00_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_BEDU_2025-523123-22-00_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_BEFR_2025-523123-22-00_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_CZ_2025-523123-22-00_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_ENG_2025-523123-22-00_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_ES_2025-523123-22-00_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_ITA_2025-523123-22-00_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_RO_2025-523123-22-00_Redacted | a |
Application history
2 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2025-10-16 | Netherlands | Acceptable with conditions 2026-02-23
|
2026-02-24 |
| 2 | SUBSTANTIAL MODIFICATION | SM-2 | 2026-03-20 | Acceptable 2026-05-07
|
2026-05-07 |